CorMedix (CRMD) Cost of Revenue (2013 - 2025)

CorMedix (CRMD) has 12 years of Cost of Revenue data on file, last reported at $11.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue rose 894.52% year-over-year to $11.2 million; the trailing twelve-month figure through Dec 2025 stood at $22.2 million (up 619.16% YoY), and the FY2025 full-year result was $22.1 million, up 628.05% from the prior year.
• Cost of Revenue advanced to $11.2 million in Q4 2025, from $7.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $11.2 million in Q4 2025 to a low of $332.0 in Q2 2022.
• A 4-year average of $1.6 million and a median of $285589.0 in 2021 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue tumbled 99.15% in 2022 and surged 1092.16% in 2025, its largest moves.
• Tracing CRMD's Cost of Revenue over 4 years: stood at $48007.0 in 2021, then plunged by 99.15% to $406.0 in 2022, then surged by 276481.53% to $1.1 million in 2024, then jumped by 894.52% to $11.2 million in 2025.
• Business Quant data shows CRMD's Cost of Revenue at $11.2 million in Q4 2025, $7.6 million in Q3 2025, and $1.9 million in Q2 2025.